Skip to search formSkip to main contentSkip to account menu

TGN-1412 monoclonal antibody

Known as: TGN 1412, monoclonal antibody TGN1412, TAB08 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Pediatric acute lymphoblastic leukemia (ALL) represents the most common pediatric cancer diagnosis, with numbers rising gradually… 
2015
2015
A phase II trial of an experimental drug that made headlines nine years ago when it caused horrific injuries to volunteers in a… 
2014
2014
The CD28 superagonist (CD28SA) TGN1412 was administered to humans as an agent that can selectively activate and expand regulatory… 
2008
2008
In March 2006, a phase I study of the superagonistic anti-CD28 antibody TGN1412 caused a massive cytokine storm and multiorgan… 
2007
2007
ZusammenfassungDer Einsatz monoklonaler Antikörper hat auf vielen klinischen Gebieten zu neuen therapeutischen Möglichkeiten gef… 
Highly Cited
2006
Highly Cited
2006
In March, after receiving injections of TGN1412, six volunteers became desperately ill, had multiple-organ failure, and were… 
2006
2006
New guidelines call for a change in the culture of research 
Review
2006
Review
2006
A current focus of cancer research is the development of immunostimulatory therapeutic antibodies, based on the notion that… 
2006
2006
In the last issue of ATLA, we assessed whether the existing methods for assessing the safety and efficacy of new candidate…